ERBB2 and fibrosarcoma: In particular, many studies have found that YAP activation empowers cancer cell to resist chemotherapies and targeted anticancer therapies including rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase (MEK), and human epidermal growth factor receptor 2 (HER2) inhibitors (Lin et al., 2015; Kim et al., 2016; Zanconato et al., 2016).